image: (a) Schematic representation of study design, experimental and computational processing including host filtration using the Human Pangenome Reference Consortium, microbial classification using Qiita and laboratory-associated decontamination with SCRub. (b) Differences in community structure represented by the RPCA-PCoA between the plasma of participants with primary liver tumour (HCC) or with metastatic liver tumour (mCRC) (RPCA-PERMANOVA, p=0.015). (c) Top and bottom 10 microbial taxa associated with primary liver tumour (HCC, green) or metastatic liver tumour (mCRC, pink).The left panel represents the differential abundance rankings from BIRDMAn. The right panel represents the relative abundances for each participant and average for each condition. BIRDMAn, Bayesian Inferential Regression for Differential Microbiome Analysis; cfDNA, cell-free DNA; HCC, hepatocellular carcinoma; mCRC, metastatic colorectal cancer; PCoA, Principal Coordinates Analysis; PERMANOVA, Permutational Multivariate Analysis of Variance; RPCA, Robust Principal Coordinates Analysis.
Credit: By Caitlin Guccione, Ana Carolina Dantas Machado, Fady Youssef, et al.
A simple blood test analyzing microbial DNA could help doctors tell apart primary liver cancer from colorectal cancer that has spread to the liver, according to a new study in eGastroenterology.
Researchers used shotgun metagenomic sequencing on blood plasma and tumor tissue samples from patients with hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). They found that microbial DNA circulating in the blood provided stronger diagnostic signals than tissue-based profiling, revealing distinct bacterial “fingerprints” for each cancer type.
In the study, plasma samples clearly separated HCC from mCRC, while tumor tissues did not. Specific bacterial groups—including Pseudomonas aeruginosa in HCC and Acinetobacter species in mCRC—emerged as potential biomarkers.
“Blood-derived microbial DNA captures signals from across the body, not just a single lesion,” said Professor Amir Zarrinpar. “This makes it a powerful, non-invasive tool for distinguishing liver cancers that often look similar on imaging scans.”
If validated in larger studies, microbial cfDNA profiling could:
- Improve accuracy when imaging results are inconclusive
- Complement existing biomarkers like alpha-fetoprotein (AFP)
- Enable earlier detection in high-risk patients with cirrhosis
- Inform treatment choices, from surgery to systemic therapy
This pioneering study demonstrates that blood microbial cfDNA can distinguish hepatocellular carcinoma from metastatic colorectal cancer in the liver. By identifying distinct microbial taxa associated with each tumor type, the research lays critical groundwork for non-invasive, microbiome-based diagnostics.
Although not yet ready for clinical use, these findings point toward a future where the microbiome becomes a powerful ally in oncology, aiding in cancer detection, prognosis, and potentially guiding therapy. As sequencing costs decline and validation studies expand, microbial cfDNA may soon join the frontline of precision cancer medicine.
See the article:
Guccione C, Dantas Machado AC, Youssef F, et al. Blood microbial DNA signature differentiates hepatocellular carcinoma from metastatic lesions. eGastroenterology 2025;3:e100193. doi:10.1136/egastro-2025-100193
About eGastroenterology
eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD, and COPE, with more to come!
For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ).
Sign-up to Email Alerts for eGastroenterology: https://emails.bmj.com/k/Bmj/jausu/egastroenterology
Journal
eGastroenterology
Article Title
Blood microbial DNA signature differentiates hepatocellular carcinoma from metastatic lesions